Testing for PSA over many years might help some men live longer by catching prostate cancer early, but only if the test is done regularly and properly — otherwise, it doesn’t seem to help.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether PSA screening definitively reduces prostate cancer mortality across diverse populations and protocols, accounting for heterogeneity in screening frequency, biopsy rates, and contamination.
A systematic review and meta-analysis of all randomized controlled trials of PSA screening (ERSPC, PLCO, CAP, Göteborg) with individual patient data, stratified by screening frequency, biopsy adherence, contamination levels, and baseline risk, using prostate cancer-specific mortality as the primary endpoint over ≥15 years.
Whether a standardized, high-adherence PSA screening protocol reduces prostate cancer mortality compared to no screening in a contemporary population.
A multicenter, double-blind RCT of 50,000 men aged 50–69, randomized to annual PSA testing with biopsy for PSA >3 ng/mL and MRI triage vs. no screening, with prostate cancer-specific mortality as primary endpoint over 20 years, and strict control of contamination and biopsy adherence.
Whether baseline PSA levels predict long-term prostate cancer mortality in a general population over decades.
A prospective cohort of 100,000 men aged 40–50 with baseline PSA measured and followed for 25+ years, recording prostate cancer diagnosis, metastasis, and death, adjusting for age, race, family history, and BMI.
Whether men who died from prostate cancer had significantly different PSA levels or screening histories compared to matched controls who did not.
A case-control study of 1,000 men who died from prostate cancer vs. 1,000 age-matched controls who died of other causes, with archived serum samples and screening history from national registries to assess PSA levels 5–20 years prior to death.
Consensus among experts on whether PSA screening should be recommended based on current evidence.
A Delphi consensus panel of 30 international urologists, oncologists, and epidemiologists rating the strength of evidence for PSA screening using standardized criteria.